Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Anthropic snatches Google AI talent and Airwallex’s AI-native finance stack push

View original at cbinsights.com
CB Insights - Enterprise Ai Title: Anthropic snatches Google AI talent and Airwallex’s AI-native finance stack push Date: 2026-07-02 22:30 Source: https://www.cbinsights.com/research/newsletter-july-2/ <p><span style="font-weight: 400;">Below, we break down some of tech’s biggest stories, with perspectives from our ana…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • OpenAI has attracted just 3 DeepMind hires over a longer window, with only 1 in the past year.

    60% confidence
  • Anthropic's headcount increased 183% over the past year, with technical roles making up over a third of its roughly 5,000-person workforce.

    60% confidence
  • CB Insights data puts the total DeepMind hires for Anthropic at 5.

    60% confidence
  • Breaks down the rise of agentic commerce and what she's seeing in the market.

    60% confidence

Data points we hold from this source

OpenAI · deepmind hires count3 employees
Anthropic · employee count growth yoy183 percent
Anthropic · deepmind hires count5 employees
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Anthropic snatches Google AI talent and Airwallex’s AI-native finance stack push — Source | Via News | Via News